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ABSTRACT
The second generation tyrosine kinase inhibitor (TKI) dasatinib is a clinically 
approved drug for chronic myeloid leukemia (CML) as well as Ph+ acute lymphoblastic 
leukemia. In addition to its antileukemic effects, dasatinib was shown to impact on 
normal hematopoiesis and cells of the immune system.
Due to the fact that the murine in vivo studies so far have not been performed 
in a chronic-phase CML model under steady-state conditions, our aim was to study 
the hematopoietic effects of dasatinib (20 mg/kg p.o.) in BCR-ABL expressing 
SCLtTAxBCR-ABL double transgenic (dtg) mice. Dasatinib robustly antagonized the 
CML phenotype in vivo in our transgenic mouse model, and this effect included both 
mature and immature cell populations. However, similar to patients with CML, the 
fraction of LinnegSca-1+KIT+CD48negCD150+ hematopoietic stem cells was not reduced 
by dasatinib treatment, suggesting that these cells are not oncogene-addicted. 
Moreover, we observed differential effects of dasatinib in these animals as compared 
to wild-type (wt) animals: while granulocytes were significantly reduced in dtg 
animals, they were increased in wt mice. And Ter119+ erythrocytic and B220+ B cells 
were increased in dtg mice but decreased in wt mice. Finally, while dasatinib induced 
a shift from CD49b/NK1.1 positive NK cells from the bone marrow to the spleen in wt 
animals, there was no change in dtg mice. In conclusion, the present mouse model 
provides a useful tool to study mechanisms of TKI resistance and dasatinib-associated 
beneficial effects and adverse events.
INTRODUCTION
Dasatinib is a second-generation ABL tyrosine 
kinase inhibitor (TKI), approved for the treatment of 
chronic myeloid leukemia (CML) and BCR-ABL-positive 
acute lymphoblastic leukemia (ALL). However, due to its 
multitarget specificity, it is also being tested in clinical 
trials for other cancers. Dasatinib has been shown to exert 
marked effects on the normal hematopoietic system [1–3]. 
In vitro, dasatinib induces immunosuppression by targeting 
key kinases of the immune system such as Lyn and 
Brutons’s tyrosine kinase (Btk), thereby inhibiting B- and 
T cell signaling [4]. Furthermore, several studies showed 
an immunomodulatory effect of dasatinb, including 
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mobilization of natural killer (NK) cells and enhanced 
NK cell cytotoxicity, both of which were not seen with 
imatinib or nilotinib [5–8]. The immunomodulatory 
function of dasatinib and the activation of large granular 
lymphocytes (LGLs) were shown to be associated 
with a better outcome, being associated with increased 
cytogenetic and molecular remissions [7, 9]. A correlation 
between LGL lymphocytosis and the development of 
autoimmune symptoms such as pleural effusions and 
colitis has been postulated [10]. Pleural effusions were 
more likely induced by accumulation of lymphocytes than 
by fluid retention alone [11].
Several studies have addressed the influence of 
dasatinib on non-malignant hematopoietic cells. Schade 
et al and Blake et al demonstrated that dasatinib inhibits 
T cell receptor (TCR) signal transduction, resulting in 
reduced proliferation and cytokine production but not 
apoptosis of T cells, if dasatinib is constantly present 
[12, 13]. Conversely, dasatinib induced apoptosis in 
human B-lymphocytes derived from peripheral blood or 
bone marrow, resulting in a strong reduction of B cells 
[2]. Through off-target inhibition of Btk, this reduction 
also resulted in reduced memory B cell numbers and 
impairment of the B cell response in dasatinib-treated 
patients [14]. Importantly, in vitro and in vivo data of 
dasatinib treatment can differ significantly in T cell but 
also NK cell differentiation and activation, due to the 
short half-life of the TKI in plasma in comparison to the 
endured presence in cell culture [15, 16].
We studied the hematopoietic effects of dasatinib 
in BCR-ABL expressing SCLtTAxBCR-ABL double 
transgenic (dtg) mice [17]. This model allows the analysis 
of dasatinib-induced effects on mature blood and immune 
cells as well as on hematopoietic stem and progenitor 
cells in BCR-ABL expressing and control mice. In 
wild-type mice, dasatinib had been shown to transiently 
activate hematopoietic stem cells (HSCs) and induce the 
proliferation of HSCs and a loss of lineage-committed 
progenitor cells, and this was associated with increases 
of stem cell factor (SCF) serum levels [18]. Given that 
our previous studies had demonstrated that BCR-ABL 
induces an increase of Lin-Sca-1+Kit+ (LSK) cells and 
granulocyte-macrophage progenitor cells (GMPs) [17], 
we now studied how dasatinib influences the proliferation 
and differentiation of hematopoietic stem and progenitor 
cells. Moreover, with our observation that BCR-ABL 
expression leads to a strong decrease of B220+ B cells 
in the bone marrow and the spleen [19], and with the 
evidence by Oksvold and colleagues shown that dasatinib 
induces apoptosis in normal B cells [2], we studied how 
dasatinib affects B- and T cells as well as NK cells in a 
CML in vivo model (both in a steady-state setting or after 
transplantation of BCR-ABL positive bone marrow stem 
cells). Finally, we studied whether dasatinib is able to 
reverse the BCR-ABL induced CML phenotype, including 
organ infiltration by myeloid cells, splenomegaly, and 
bone marrow stem and progenitor cell expansion.
RESULTS
Dasatinib-induced changes of the 
immunophenotype in wild-type mice
In this study, we evaluated the effect of dasatinib 
on different cell types in bone marrow (BM), spleen and 
peripheral blood (PB) by FACS analysis. An overview of 
the different mice and treatment schedules is depicted in 
Supplementary Figure 1.
We analyzed the immunophenotype in BM and 
spleen of 8 week old FVB/N wt mice treated for 14 days 
with 5 or 20 mg/kg dasatinib compared to vehicle control 
(5% DMSO in citrate buffer). The concentrations where 
based on previous in vivo experiments [12, 20]. The last 
dosing of dasatinib was performed on the day before the 
final analysis. Flow cytometry measurements revealed a 
significant increase of Gr1 positive granulocytes in the BM 
and spleen that was associated with a significant reduction 
of the fraction of lymphocytes (Figure 1A). This was due 
to a significant increase of CD11b positive cells with high 
coexpression of Gr1 (mature granulocytes; 1.8- and 5.6-
fold in BM and spleen, resp.) but not low Gr1 coexpression 
(immature granulocytes) (Figure 1B). Interestingly, this was 
only seen with the higher dose (20 mg/kg) but not the lower 
dose (5 mg/kg) of dasatinib.
Both doses of dasatinib significantly increased 
CD41+ megakaryocytic cells in the spleen as well as 
with 5 mg/kg dasatinib in the BM, while the fraction 
of these cells was significantly reduced in the BM 
with 20 mg/kg dasatinib (Figure 1C). The fraction of 
Ter119+ erythroid cells was significantly decreased 
in BM and spleen after 20 mg/kg dasatinib treatment 
(Figure 1C).
Spleen weight was slightly, but significantly reduced 
with the higher but not the lower dose of dasatinib (Figure 
1D). Higher doses of dasatinib (20 mg/kg) induced a 
significant decrease of the fraction of B220+ B lymphocytes 
in the BM and spleen, while lower doses did not (Figure 1E). 
Furthermore, the fraction of CD4+ T cells was significantly 
reduced in the BM, while CD3+ and CD8+ cells were not 
changed (Figure 1E), and there were no changes of CD3+, 
CD4+, or CD8+ cells in the spleen (Supplementary Table 
1A). The ratio between CD4 and CD8 positive CD3+ cells 
was not altered (data not shown). Finally, dasatinib (only 20 
mg/kg shown) induced a significant increase of the fraction 
of NK1.1/CD49b double positive NK cells in the spleen 
but a decrease in the BM, suggesting mobilization of NK 
cells from the BM to the spleen (Figure 1F). Analysis of 
lymphocytes for the expression of CD49b and NK1.1 alone, 
demonstrated a significant reduction of CD49b+ lymphocytes 
after 20 mg/kg dasatinib in the BM and a similar trend for 
NK1.1+ cells (Supplementary Figure 2A–2B). There was 
no difference between male and female mice regarding the 
response to dasatinib (data not shown).
Based on the more pronounced effects of the higher 
dose of dasatinib (20 mg/kg) and in order to optimize 
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Figure 1: Dasatinib induced effects in wild-type FVB/N mice. Wild-type animals were treated for 14 days with vehicle control 
(n = 10; green), 5 mg/kg (n = 8; light blue) or 20 mg/kg dasatinib (n = 9; dark blue) and the spleen and bone marrow (BM) cells were 
analyzed by FACS. (A) Percent of Gr1 positive granulocytes (gated on living cells), as well as percentage of lymphocytes (% gated on 
FCSlow/SSClow). (B) Differentiation of mature (Gr1 high/CD11b expression) and immature (Gr1 low/CD11b expression) granulocytes in 
BM and spleen. (C) Evaluation of the percentage of megakaryocytes (CD41+) and erythroid cells (Ter119+) in BM and spleen gated on 
living cells. (D) Analysis of the spleen revealed a significant loss of spleen weight after 20 mg/kg dasatinib. (E) Detailed characterization 
of lymphocytes by staining for B220+ (B cells), CD3, CD4 and CD8 (T cells) in BM and spleen. (F) Natural killer cells (NK cells) stained 
for CD49b and NK1.1 double positivity in the BM and the spleen. All data are shown as mean ± SD. *p < 0.05.
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inhibition of the ABL kinase in the BCR-ABL positive 
mice, we conducted all of the following experiments using 
this concentration.
Changes of the immunophenotype after 
transplantation of BCR-ABL positive bone 
marrow are reverted by dasatinib treatment of 
the recipient mice
As different studies showed an immunomodulatory 
effect of dasatinib in patients with CML and we detected 
an increase of NK cells in the spleen of wt animals, we 
tested dasatinib in our CML mouse model.
For our experimental setup, we induced primary 
donor FVB/N CD45.1+ SCLtTA single transgenic (stg) 
and SCLtTAxBCR-ABL double transgenic (dtg) animals 
for 7 days (withdrawal of tetracycline) prior to BM 
isolation and transplantation into irradiated mice. This 
transplantation model allows for the detection of cell-
intrinsic effects of BCR-ABL positive cells. As expected, 
immunophenotyping of the pooled bone marrow showed 
an increase of the fraction of granulocytes in the dtg donor 
mice (Supplementary Figure 3A). After 9 days of dasatinib 
or vehicle treatment, we sacrificed the mice for analysis 
(controls: n=6/group, stg dasa: n=5, dtg dasa: n=3). Due 
to the transplantation, we detected high percentages of 
granulocytes in the BM of BCR-ABL positive as well as 
stg animals (Figure 2A). The fraction of Gr1+ cells was 
increased in the spleen of dtg vs control mice, but there 
was no change with dasatinib (Figure 2A). The fraction of 
total lymphocytes in the BM and the spleen of transplanted 
mice was slightly decreased in BCR-ABL positive mice, but 
was not significantly affected by dasatinib (Figure 2A). The 
fraction of CD41+ cells (megakaryocytes) in the BM was 
not altered by either BCR-ABL expression nor affected by 
dasatinib (Figure 2B). However, in the spleen, the fraction 
of CD41+ cells was more than 2-fold elevated in dtg mice, 
but this effect was not reversed by dasatinib (Figure 2B). 
As described before, the fraction of Ter119+ erythroid 
cells was decreased in the BM of BCR-ABL positive mice 
and reversed by dasatinib (even though this did not reach 
statistical significance), while there was no significant BCR-
ABL induced change of Ter119+ cells in the spleen; yet, the 
fraction of these cells was increased in the spleen of BCR-
ABL positive but not control mice (Figure 2B).
The BM of BCR-ABL expressing mice showed a 
significant decrease of the fraction of B220+ B cells, and this 
effect was reverted by dasatinib (Figure 2C). Interestingly, 
while the fraction of B220+ cells was also reduced in the 
spleen of BCR-ABL positive mice, dasatinib treatment did 
not revert this effect in the spleen (Figure 2C).
BCR-ABL positive mice showed a significant increase 
in the fraction of CD3+, CD4+, and CD8+ T cells in the BM, 
and this effect was reversed by dasatinib (Figure 2C). No 
significant differences in the fraction of CD3+, CD4+, and 
CD8+ T cells were observed in the spleen after dasatinib 
treatment (Supplementary Table 1B). Analysis of CD49b+ 
lymphocytes showed an increase in the BM of dtg mice 
that were significantly reduced after dasatinib treatment 
(Supplementary Figure 3B). In the spleen, no changes were 
seen in CD49b+ lymphocytes (data not shown).
Dasatinib prolongs survival of transgenic 
BCR-ABL expressing mice and reverses BCR-
ABL induced changes but does not induce 
lymphocytosis
Since the transplantation procedure used for 
the previous experiments may have altered some of 
the dasatinib-induced effects due to the prolonged 
manifestation of complete hematopoiesis, we additionally 
assessed the influence of dasatinib treatment under steady-
state conditions (without the need for BM transplantation). 
For these experiments, we induced the expression of BCR-
ABL in double transgenic (dtg) mice at day 1 and treated 
these mice with control vehicle or 20 mg/kg dasatinib 
starting at day 2.
Dasatinib significantly prolonged the survival of 
BCR-ABL positive (dtg) mice (Figure 3A). Based on these 
results, we again induced the expression of BCR-ABL 
directly in primary dtg animals and started the gavage after 1 
day without tetracycline with 20 mg/kg dasatinib or vehicle 
control and analyzed the mice after 7 days of treatment (n=4/
group). The last dosing was 1 hour before the analysis. In 
these BCR-ABL positive mice, dasatinib induced a reduction 
of the fraction of Gr1+ cells in spleen, peripheral blood 
(PB) (both significant) and BM (non-significant) (Figure 
3B). Conversely, there was a dasatinib-induced increase of 
total lymphocytes (as assessed by FSClo and SSClo profile), 
particularly in the BM (Figure 3B). When analyzing 
different subsets of Gr1+ cells, dasatinib most strongly 
reduced the fraction of Gr1 high (mature) granulocytic cells 
in the spleen (with a similar trend in BM), while the effect in 
Gr1 low (more immature) granulocytes was less pronounced 
(Figure 3c). As in wild-type animals (Figure 1C), dasatinib 
reduced the fraction of CD41+ cells in the BM (no change 
in spleen or PB) (Figure 3D). However, different from wild-
type mice (Figure 1C), dasatinib increased the fraction of 
Ter119+ cells in the BM (no significant change in spleen or 
PB) (Figure 3D).
The fraction of B220+ B cells was strongly increased 
in BM and spleen (Figure 3E) as seen in the transplantation 
setting, both indicative of a reversal of BCR-ABL induced 
suppression of B cells. The fraction of CD3+, CD4+, and 
CD8+ cells in BM and spleen was reduced by dasatinib 
(Figure 3E; changes significant from CD3+ and CD8+ 
cells). Analysis of the spleen weight revealed a clinically 
relevant 34% decrease (Figure 3F), which did not reach 
statistical significance, possibly due to the short time 
course of treatment. There was no consistent change of 
CD49b/NK1.1 double positive NK cells in the presence of 
dasatinib (Figure 3G), but analysis of CD49b and NK1.1 
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Figure 2: Transplantation of BCR-ABL expressing BM cells influences the immunophenotype of the recipient mice and 
the dasatinib effect. The expression of BCR-ABL was induced in double transgenic (dtg) donor animals and pooled for transplantation 
of 1x106 BM cells in comparison to BM of SCLtTA single transgenic (stg) control mice. (A) After 15 weeks of induction, the mice were 
treated for 9 days with control vehicle (green circles) or 20 mg/kg dasatinib (blue triangle) (control: stg/dtg: n = 6/6; dasatinib stg/dtg: n = 
5/3). Depicted are the percentages of Gr1 positive granulocytic cells and FCSlow/SSClow (lymphocytes) gated on living cells in the BM and 
the spleen of stg in comparison to dtg mice after dasatinib treatment. (B) Analysis of the percentage of CD41 positive megakaryocytes and 
Ter119 positive erythroid cells in BM and spleen of vehicle and dasatinib treated mice, gated on all living cells. (C) Percentage of B220+ 
lymphocytes was evaluated in BM and spleen. Distribution of T cells (CD3, CD4, CD8) in the BM of stg and dtg control or dasatinib treated 
mice (gated for % of FCSlow/SSClow (lymphocytes)). All data are shown as mean ± SD. *p < 0.05.
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Figure 3: Dasatinib treatment of primary induced mice results in prolonged survival of dtg animals and a reversion 
of the disease phenotype. Expression of BCR-ABL was induced for 1 day by withdrawal of tetracycline from the drinking water of stg 
(control, BCR-ABL negative) and dtg (BCR-ABL positive) mice. (A) Kaplan-Meier survival curve of induced double transgenic (dtg) mice 
receiving either vehicle control (green) or dasatinb (blue). (B) Based on the rapid disease onset in the dtg mice, we induced 8 dtg animals 
for 1 day and subsequently treated for 9 days with 20 mg/kg dasatinib (blue triangle) or vehicle control (green circle) by oral gavage (n=4/
group). Evaluation of granulocytes (Gr1) and lymphocytes (% of FCSlow/SSClow) in the bone marrow (BM), spleen and peripheral blood 
(pB). Depicted are the percentages of living cells. (C) Analysis of the amount of mature (Gr1 high/CD11b+) and immature (Gr1 low/CD11+) 
granulocytes in the BM and spleen gated on living cells. (D) Percentage of megakaryocytes (CD41) and erythroid cells (Ter119) in BM, 
spleen and pB. (E) Analysis of lymphocytes by staining for B220 (B cells) and CD3, CD4 and CD8 (T cells). Shown are the percentages of 
lymphocytes (FCSlow/SSClow). (F) Total spleen weight of vehicle treated and dasatinib treated dtg mice. (G) Effect of dasatinib on CD49b/
NK1.1 double positive NK cells in the BM, spleen and blood. (H) Microscopic evaluation of 200 cells in bone marrow smears support the 
FACS data by showing a decrease of myelocytes, promyelocytes (white arrows) and monocytes and a significant increase in lymphocytes 
after dasatinib gavage. Shown are two representative Pappenheim stainings from a vehicle treated mouse (upper picture) and a dasatinib 
treated mouse (lower picture) (100x magnification). All data are shown as mean ± SD. *p < 0.05.
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single positive lymphocytes revealed a significant decrease 
after dasatinib treatment (Supplementary Figure 4A–4B) 
that was not seen when gated on all living cells (data not 
shown). Differential cell counts of the BM confirmed 
our FACS data by showing a significant increase in 
lymphocytes and a significant decrease of monocytes, 
as well as a (non-significant) reduction of myelocytes 
and promyelocytes (Figure 3H). Single transgenic (stg) 
animals were treated as a control cohort (n=5 per group) 
and were analyzed after administration of dasatinib for 
11 times, applying the last dose 1 hour before the final 
analysis (Supplementary Table 3).
Dasatinib induced changes in the stem and 
progenitor compartment of BCR-ABL 
expressing mice
CML is a stem cell disorder with expression of 
BCR-ABL in various hematopoietic lineages that is 
mimicked in the SCLtTAxBCR-ABL mouse model. The 
percentage of Lin-Kit+Sca-1+ (LSK) cells, which are 
enriched for HSCs, was shown to be increased in induced 
dtg mice, as well as an expanded GMP (granulocyte-
macrophage progenitor) pool, presumably resulting in 
neutrophilia, as described [17]. We analyzed the stem and 
progenitor compartment of our dtg animals after 7 days 
of dasatinib treatment. The gating strategy was adapted 
from [21] and is depicted in Figure 4A. There was a 
significant decrease of the fraction of LSK cells as well 
as the multipotent progenitor-1 (MPP1) population in the 
dasatinib treated animals (Figure 4B). Interestingly, this 
was associated with a significant increase in the fraction of 
phenotypic LT-HSCs (long-term hematopoietic stem cells) 
compartment, suggesting that these most immature HSCs 
were spared by dasatinib (Figure 4B). The short term-HSC 
(ST-HSC) and MPP2 populations were not significantly 
altered (Figure 4B). The analysis of the myeloid 
progenitor cells demonstrated a significant increase in the 
fraction of MEPs (megakaryocyte-erythroid progenitors) 
by dasatinib, while GMPs and CMPs (common myeloid 
progenitor) fractions were reduced by dasatinib although 
this did not reach significance. We confirmed reduction of 
BCR-ABL kinase activity by Western blotting of lysates 
generated from unfractionated BM or spleen cells of the 
dtg mice described in Figure 3, with phosphorylation 
levels of STAT5 and Crkl being strongly reduced by 
dasatinib treatment (Figure 4C).
Histological changes of the lung and intestine 
after dasatinib treatment
While clearly beneficial for a large proportion 
of patients with CML, dasatinib treatment has been 
associated, among other signs and symptoms, with adverse 
events such as pleural effusions, colitis, or pulmonary 
hypertension [22]. Interestingly, pleural effusion or colitis 
were associated with a favorable outcome of the patients 
with increased cytogenetic and molecular remission [7, 9, 
23]. Therefore, we analyzed whether dasatinib treatment 
was associated with such adverse events or signs for the 
latter in the mice studied. Gross pathology analysis did not 
show any clinically relevant pleural effusion.
Evaluation of lung histologies was performed by 
measurements of the thickness of muscularis propria of 
lung arteries and height of bronchus epithelium as depicted 
in Figure 5. We analyzed three vessels/bronchi per mouse 
at three different positions and calculated the mean values 
per lung. In our transplantation model, we saw a slight 
reduction in thickness in both, muscularis media and 
bronchial epithelium in the dasatinib treated stg but not dtg 
mice, however, this did not reach statistical significance 
(Figure 5A). This was confirmed in the primary transgenic 
mice (without transplantation) which also showed no 
significant change in arterial vessels or bronchus epithelia 
thickness after dasatinib treatment (Figure 5B).
There was no dasatinib-induced colitis evident 
in our mouse model, at least during the short course of 
dasatinib treatment. In colon mucosa, no changes between 
the two groups could be seen, but cytochemical NACE 
staining of the small intestine revealed an infiltration 
within the epithelium and less in the lamina propria by 
granulocytes in the BCR-ABL expressing mice, which 
was decreased after treatment with dasatinib (Figure 6).
DISCUSSION
In this study, we report in vivo effects of dasatinib on 
the cellular composition of the hematopoietic and immune 
system in wild-type mice as well as in a tetracycline-
inducible transgenic mouse model of BCR-ABL positive 
CML-like disease. We analyzed dasatinib-induced effects 
by flow cytometry in the bone marrow (BM) and spleen 
under steady-state conditions as well as after bone 
marrow transplantation. Furthermore, we conducted flow 
cytometry analysis of stem- and progenitor cells in the BM 
of BCR-ABL expressing mice treated with dasatinib or 
vehicle control and performed histopathology to evaluate 
effects on the BM, spleen, lung and intestine.
Dasatinib has been previously shown to inhibit 
neutrophil function in vitro and in vivo in mice, but 
effects of dasatinib on neutrophil counts were not 
reported [24]. We found that 20 mg/kg of dasatinib 
increased granulocytic cells in normal experimental mice 
(Figure 1A). Yet, in BCR-ABL positive mice, dasatinib 
decreased granulocytic cells. This discrepancy may have 
been due to efficient inhibition of BCR-ABL positive 
granulocytic cells by dasatinib but failure to induce non-
leukemic granulocytes due to insufficient residual normal 
hematopoiesis. In fact, this is very reminiscent of patients 
with newly-diagnosed CML, where dasatinib causes 
neutropenia. As described previously [17], BCR-ABL 
expression in our transgenic mice induced a decrease of 
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Figure 4: Dasatinib alters the stem- and progenitor cell compartment of BCR-ABL expressing mice. After 9 days of 
treatment with 20 mg/kg dasatinib (blue triangle) or vehicle control (green circle), the stem and progenitor cells in the bone marrow (BM) 
of BCR-ABL expressing mice were analyzed by FACS staining (n = 4/group) (A) Gating strategy for differentiation of stem cells and 
progenitor cells. (B) Stem cells were subdivided into LSK cells (lin-, c-kit+, Sca-1+) that were further characterized for expression of CD48 
and CD150. Short-term (ST-, CD48-, CD150-) and long term (LT-, CD48-, CD150+) hematopoietic stem cells (HSC) and multi-potent-
progenitor: MMP2 (CD48+, CD150-), MPP1 (CD48+, CD150+). The progenitor cells were also gated on lin- cells that were analyzed for 
high expression of c-kit and low Sca-1 expression (MPs). Further differentiation was done by staining for CD34 and CD16/32. MEPs 
(megakaryocyte-erythroid progenitors) that were CD34 low and CD16/32 positive, while GMP (granulocyte-macrophage progenitor) were 
positive for both and CMPs (common myeloid progenitor) having lower CD16/32 expression but also high CD34 expression. Depicted are 
the mean values ± SD. *p < 0.05. (C) Western Blot analysis of lysed bone marrow cells as well as spleen cells. Lysates of dasatinib treated 
mice show less STAT5 and Crkl phosphorylation in comparison to lysates of vehicle treated mice. The indicated antibodies were used for 
immunostaining. GAPDH served as loading control.
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Figure 5: Histological staining and evaluation of the thickness of the lung bronchial epithelium and arteries. Analysis 
of the lung histologies was done on paraffin embedded tissue and hematoxylin and eosin (HE) stained slides. (A) Evaluation of the lung 
vessels in the transplanted FVB/N mice. The size of the bronchial epithelium (B) was measured at three different positions, as well as the 
thickness of the artery walls (A). This measurement was done at three different positions of the lung and the mean value per mouse was 
calculated. The bar graph shows the mean thickness in μm of the different groups (single transgenic (stg): vehicle n = 6, dasatinib n = 5; 
double transgenic (dtg): vehicle n = 5, dasatinib n = 3). (B) Representative pictures of the lung histologies of vehicle (upper panel) and 
dasatinib (lower panel) treated BCR-ABL expressing mice. Scale bar: 100 μm. Four mice per group were analyzed and depicted are the 
mean values per mouse ± SD of the bronchial epithelium and the artery walls.
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Ter-119 positive erythropoietic cells. Similar to the results 
in the granulocytic and megakaryocytic lineage, there 
was a pronounced effect of dasatinib on the BCR-ABL 
expressing cells, with a recovery of Ter-119 cells in the 
BM and spleen. This was due to recovered erythropoietic 
cell production after dasatinib treatment, as shown by the 
observed MEP increase in the BM (Figure 4B). Previous 
studies demonstrated a KIT-induced inhibition of the first 
steps of erythroblast differentiation that can be restored by 
dasatinib, additionally explaining our findings [25].
Analysis of the lymphocytes of wild-type mice 
revealed a decrease of B220+ B cells upon 20 mg/kg 
dasatinib treatment, consistent with previous studies that 
had shown this to be associated with apoptosis of mature 
B cells and a differentiation block in the immature B 
cell population [2]. Lower doses may efficiently inhibit 
B cell development through inhibition of B cell receptor 
signaling but may not be sufficient to induce apoptosis 
[26]. B cell depletion in our BCR-ABL expressing mice 
was reversed by dasatinib, which is in keeping with a 
BCR-ABL mediated block in B cell differentiation [27] 
as well as induction of apoptosis of BCR-ABL positive 
lymphoid cells [28].
In patients, a clonal expansion of cytotoxic T and 
NK cells was observed during dasatinib treatment that was 
associated with better therapy response and autoimmune-
like adverse reactions [7]. It was hypothesized that the 
inhibition of immunoregulatory kinases by dasatinib 
may activate a reversible immune reactivity resulting 
in good clinical response. These effects were reported 
to be concurrent with large granular lymphocyte (LGL) 
lymphocytosis in the majority of cases [10]. This LGL 
lymphocytosis in the peripheral blood (PB) was not 
detected in our transgenic mouse model within 7 days of 
dasatinib treatment (data not shown), but onset of LGL 
lymphocytosis varied between one and eight months after 
initiation of dasatinib therapy in patients [10]. FACS 
analysis of BM and spleen of dasatinib-treated wt animals 
revealed a reduction of CD4 positive T cells in the BM 
after 14 days, while the CD3 and CD8 positive cells were 
not affected. These results are in line with the finding 
that T cell proliferation was inhibited by dasatinib in a 
dose-dependent manner in an in vivo mixed lymphocyte 
reaction experiment after adoptive transfer of donor 
CD4+ T cells in allogenic donors [12]. There was a strong 
increase in the fraction of T cells in the BM and spleen 
Figure 6: Reduced infiltration of the small intestine by granulocytes in dasatinib treated dtg mice. The accumulation 
of granulocytes in the folds of the small intestine of dtg (double transgenic) mice was demonstrated by immunohistochemistry (NACE 
staining). Dasatinib treatment of dtg mice strongly reduced the amount of granuloytic infiltration. Scale bar: 250 μm and 50 μm.
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of BCR-ABL mice, both under steady-state conditions 
and after BM transplantation, which was antagonized 
by dasatinib treatment (Figure 2C and 3E). Previous 
studies demonstrated a reduced amount of NK cells, as 
well as functional defects of NK cells in CML patients 
at diagnosis [29, 30]. Interestingly, in wt mice, dasatinib 
led to a decrease of NK1.1/CD49b double positive cells 
in the BM but an increase in the spleen, suggesting that 
it enhanced migration of these cells from the BM to 
the spleen. However, dasatinib treatment of BCR-ABL 
positive mice did not significantly alter NK cells. With a 
link between LGL lymphocytosis and cytomegalovirus 
(CMV) reactivation having been established in CML 
patients [5], this may not have been mimicked in our BCR-
ABL mice due to breeding in isolated ventilated cages. 
Dasatinib efficiently normalized the LSK, MEP, CMP and 
GMP fractions in BCR-ABL positive mice with associated 
normalizations of Gr1+ and Ter119+ cell populations. 
However, phenotypic LT-HSCs were spared by dasatinib 
and their fraction increased. This finding closely reflects 
reports in CML patients and patient-derived immature 
CD34+CD38- cells that CML stem cells are spared by 
treatment with TKIs, including dasatinib [28, 31, 32].
To evaluate the occurrence of dasatinib-associated 
pleural effusion, pulmonary artery hypertension, or colitis, 
we analyzed the effects on different organs, focusing on the 
lung and the small intestine, but no evidence for dasatinib 
induced alterations of the lung or colon were observed. 
This may have been due to the short duration of dasatinib 
treatment or to fundamental differences in murine and 
human immune effects. Nevertheless, dasatinib strongly 
counteracted BCR-ABL induced granulocytic infiltration 
of the small intestinal mucosa (Figure 6).
In conclusion, we demonstrate that dasatinib 
strongly antagonizes BCR-ABL induced effects in vivo 
in a transgenic mouse model of chronic phase-CML, 
but had differential effects on hematopoiesis in wt 
mice. Short-term exposure to dasatinib did not induce 
significant LGL lymphocytosis, pleural effusion or signs 
of pulmonary artery hypertension. This mouse model is 
useful to investigate short-term effects of dasatinib and 
TKI resistance but may also be utilized for assessment of 
the mechanisms of long-term effects of CML treatment.
MATERIALS AND METHODS
Mouse experiments
The SCLtTAxBCR-ABL double transgenic (dtg) 
mouse model has been described previously [17]. The mice 
are bred in-house and genotyped with the following primers: 
tTA forward 5′-GCTAGGTGTAGAGCAGCCTAC-3′ and 
reverse 5′-GGC GGC ATAC TAT CAG TAG TA-3′ and 
BCR-ABL forward 5′-GAG CGT GC AGA GTG GAG 
GGA GAA CA-3′and reverse 5′-GGT ACC AGG AGT 
GTT TCT CCA GAC TG-3′. In these mice, the expression 
of BCR-ABL is induced by withdrawal of tetracycline from 
the drinking water.
Using 8 week old FVB/N wild-type animals 
purchased from Janvier Labs (France) that were male/
female and age matched, two doses of dasatinib were 
tested, with 5 mg/kg vs. 20 mg/kg dasatinib (provided 
by Bristol-Myers Squibb) being administered by oral 
gavage for 14 days. For transplantation experiments, 
bone marrow (BM) of 4 mice that had been offset from 
tetracycline for seven days, was pooled and transplanted 
1x106 cells (2.5x105 BCR-ABL positive cells; 7.5x105 
single-transgenic control cells) into irradiated (10 Gy) 
FVB/N CD45.2+ recipient mice. Afterwards, the disease 
phenotype was assessed by regular blood counts and 
flow-cytometric analysis for Gr1/CD11b+ cells. After 15 
weeks of induction, oral gavage treatment with 20 mg/
kg dasatinb or control vehicle (80 mM citric acid stock 
solution (pH 2.1) in 80 mM citrate buffer (pH 3.1)) was 
begun and performed for 10 days. The SCLtTAxBCR-
ABL mouse strain expresses CD45.1, therefore allowing 
distinction between donor (CD45.1) and recipient 
(CD45.2) hematopoiesis.
In another approach BCR-ABL, expression was 
induced in single-transgenic (stg) control and double-
transgenic (dtg) BCR-ABL positive animals, and the mice 
were treated daily with 20 mg/kg dasatinib for survival 
analysis. In another cohort of mice, the effect of dasatinb 
in dtg mice was analyzed after 7 days of treatment.
All animal experiments were approved by the 
local authorities of North Rhine-Westphalia, Germany 
(Landesamt für Natur, Umwelt und Verbraucherschutz 
NRW).
Dasatinib treatment
Two different batches of dasatinib obtained from 
Bristol-Myers Squibb (BMS) were used. For the first 
experiment, dasatinib was dissolved in DMSO, diluted in 
80 mM citrate buffer (pH 3.1), and used in comparison 
with citrate buffer with 5% DMSO (vehicle control). The 
other batch was prepared as a 30 mg/ml stock solution by 
sonication in 80 mM citric acid stock solution (pH 2.1). 
This stock was renewed every five days and diluted daily 
in 80 mM citrate buffer (pH 3.1) before dosing. Dasatinib 
was applied once daily with 5 or 20 mg/kg or citrate buffer 
vehicle by oral gavage. Both batches produced comparable 
results.
Flow cytometry analysis
Bone marrow cells were isolated from two tibias and 
femurs of each mouse by flushing with PBS supplemented 
with 2% fetal calf serum (FCS). Peripheral blood was 
obtained by retro-orbital bleeding. Spleen cells were 
freshly prepared by a 100 μm cell strainer (Greiner Bio-
one, Frickenhausen, Germany). Enucleated red blood 
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cells were lysed with ammonium-chloride-potassium 
buffer (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM Na2-
EDTA, pH 7.3) prior to incubation with the appropriate 
FACS antibodies. The following antibodies were used for 
the phenotyping of the immune cells by FACS analysis: 
Gr1, CD45.1, B220, CD4, CD11b, CD8, Ter-119, CD3, 
NK1.1 (Biolegend, Fell, Germany), CD41 (eBioscience, 
Frankfurt, Germany), CD49b (BD Bioscience, Heidelberg, 
Germany). 1x106 cells were stained for 15 minutes on ice 
and washed with PBS/FCS.
For stem- and progenitor cell analysis, cells were 
stained for lineage positive cells with tricolor- or PE-
Cy5 labeled CD4, CD8a, B220 (life technologies, 
Germany) CD3 (BD Bioscience), Gr1, Ter-119, CD11b 
(Biolegend). Lineage negative cells were further 
characterized by CD48, CD150, c-kit (Biolegend) and 
Sca-1 (biotin labeled first antibody and streptavidin Pe-
Cy7 labeled secondary antibody, BD Bioscience) for 
the stem cell compartment, and CD127, c-kit, CD34 
(Biolegend), CD16/32 (BD Bioscience) and Sca-1 
for progenitor staining. FACS measurements were 
conducted with a FACS Gallios (Beckman Coulter, 
Krefeld, Germany) and analyzed with Kaluza Software 
(Version 1.3) or FlowJo (Version 10).
Histology and cytology
The organs were fixed in neutrally buffered 4% 
formalin before embedding in paraffin. Afterwards, 
the sections were stained with hematoxylin and eosin 
(HE) or naphthyl acetate (chloro-)esterase (NACE). 
Histological figures and quantitative evaluation of 
lung specimen were done using NPD.view2 software 
(Hamamatsu) by measuring maximum extend of 
bronchial epithelia or smooth muscle cells of arterial 
vessels at three positions in the lung, three measurements 
each. Blood and bone marrow smears were prepared 
and Pappenheim stained for the differentiation of the 
hematopoietic cells (100 cells in the blood smear and 
200 in the bone marrow).
Preparation of cell lysates, SDS-PAGE, and 
immunoblotting
Cell lysates were prepared, and SDS-PAGE as 
well as immunoblotting was performed as described 
before [33]. Proteins on PVDF membrane were detected 
via chemoluminescence (Fusion SL, PeqLab, Erlangen, 
Germany). The following antibodies were used: polyclonal 
rabbit anti-mouse/human phospho-STAT5 (Tyr694, #9351) 
and phospho-Crkl (Tyr207, #3181) ordered from Cell 
Signaling/New England Biolabs (Frankfurt, Germany). 
c-Abl (sc-131), GAPDH (sc-32233) and STAT5 (sc-835) 
antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA).
Statistical analysis
GraphPadPrism software was used for the statistical 
analysis. The two-tailed Student’s t-test or Wilcoxon-
Mann-Whitney-test were performed, defining significant 
differences as *P < 0.05, **P < 0.01, ***P < 0.001. Mean 
and standard deviation (SD) are indicated.
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